세계의 선양낭포암 시장 - 산업 규모, 동향, 기회, 예측, 약제 클래스별, 치료별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Adenoid Cystic Carcinoma Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Treatment, By Distribution Channel By Region and Competition, 2020-2030F
상품코드:1698035
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
선양낭포암 세계 시장은 2024년 2억 1,806만 달러에 달했고, 2030년까지 예측 기간 동안 5.42%의 연평균 복합 성장률(CAGR)로 성장을 이룰 것으로 예상됩니다.
세계 선양낭포암 시장은 종양 치료제 및 진단 의약품의 광범위한 전망에서 중요한 부분을 차지하고 있습니다. 선형낭종암(ACC)은 드물지만 침습적인 암으로 침샘에 주로 발생하지만 유방, 폐, 기관 등 다양한 장기에 영향을 미칠 수 있는 희귀한 암입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
2억 1,806만 달러
시장 규모 : 2030년
2억 9,687만 달러
CAGR : 2025-2030년
5.42%
급성장 부문
온라인 약국
최대 시장
북미
시장 성장 촉진요인
정밀의료의 발전
주요 시장 이슈
제한된 치료 옵션
주요 시장 동향
바이오마커 기반 접근법
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 선양낭포암 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별(세포 독성약, 티로신키나아제 억제제, 단일클론항체, 기타)
치료별(수술, 방사선 요법, 화학요법, 표적치료)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
약제 클래스별
치료별
유통 채널별
지역별
제5장 아시아태평양의 선양낭포암 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
약제 클래스별
치료별
유통 채널별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 선양낭포암 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 선양낭포암 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 선양낭포암 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 선양낭포암 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
이집트
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제12장 세계의 선양낭포암 시장 : SWOT 분석
제13장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Ayala Pharmaceuticals.
Amgen Inc.
CureVac AG
Elevar Therapeutics
Actuate Therapeutics
Prelude Therapeutics
Merck Sharp & Dohme Corp.
Elly Lilly and Company
Celgene Corporation
OncoMed Pharmaceuticals.
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Adenoid Cystic Carcinoma Market was valued at USD 218.06 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.42% through 2030. The Global Adenoid Cystic Carcinoma Market represents a vital segment within the broader landscape of oncology therapeutics and diagnostics. Adenoid Cystic Carcinoma (ACC) is a rare and often aggressive form of cancer that typically originates in the salivary glands but can also affect various other organs, such as the breast, lung, and trachea.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 218.06 Million
Market Size 2030
USD 296.87 Million
CAGR 2025-2030
5.42%
Fastest Growing Segment
Online Pharmacies
Largest Market
North America
Key Market Drivers
Advancements in Precision Medicine
Advancements in Precision Medicine have emerged as a significant catalyst for the growth and transformation of the Global Adenoid Cystic Carcinoma (ACC) Market. Precision medicine represents a revolutionary approach to healthcare, particularly in the context of ACC, a rare and diverse cancer that has historically posed significant treatment challenges. This paradigm shift is primarily fueled by the recognition that each ACC patient's tumor has a unique molecular profile, demanding tailored therapeutic strategies. For instance, according to a 2024 article, immunohistochemical analysis of MYB expression is highly specific and sensitive for identifying the solid variant of adenoid cystic carcinoma of the breast among triple-negative breast cancers. This method offers a valuable diagnostic tool for distinguishing this rare cancer subtype from other triple-negative cases, as well.
Key Market Challenges
Limited Treatment Options
Adenoid Cystic Carcinoma (ACC), a rare and often aggressive cancer, poses significant challenges in terms of treatment options, which has been a persistent hindrance to progress in the Global Adenoid Cystic Carcinoma Market. While advancements have been made in recent years, the limited array of available therapies remains a primary concern for both patients and healthcare providers.
Historically, surgery, radiation therapy, and chemotherapy have been the primary treatment modalities for ACC. However, these approaches often come with substantial drawbacks. Surgery, while effective for localized tumors, may not be feasible in cases where ACC has infiltrated critical structures or organs. Radiation therapy, though useful, can cause long-term side effects, and chemotherapy has shown limited efficacy against ACC, with a high potential for adverse reactions. The scarcity of treatment options has led to a pressing need for innovative and more effective therapies tailored specifically to ACC. Although targeted therapies and immunotherapies have shown promise in clinical trials, these treatments are still in their developmental stages and may not be accessible to all ACC patients.
Key Market Trends
Biomarker-Driven Approaches
Biomarker-driven approaches are playing a pivotal role in boosting the Global Adenoid Cystic Carcinoma (ACC) Market. ACC, a rare and heterogeneous cancer, has long presented challenges in terms of treatment personalization due to its varied genetic subtypes and clinical behaviors. However, the emergence of biomarker-driven approaches has ushered in a new era of precision medicine, offering tailored treatments that are transforming the landscape of ACC management.
The essence of biomarker-driven approaches lies in the identification of specific biological markers or genetic signatures within an individual patient's tumor. These markers serve as indicators of the tumor's molecular characteristics, helping healthcare providers make informed decisions about the most suitable treatment regimen. In the case of ACC, where tumor heterogeneity is pronounced, this level of precision is paramount.
One of the notable biomarkers in ACC is the MYB-NFIB fusion gene, which is a common genetic alteration found in a subset of ACC cases. Identifying this fusion gene allows clinicians to categorize the tumor accurately and select therapies that align with its unique genetic profile. For example, targeted therapies designed to disrupt the MYB pathway have shown remarkable promise in clinical trials for ACC patients with this specific biomarker.
Key Market Players
Ayala Pharmaceuticals
Amgen Inc.
CureVac AG
Elevar Therapeutics
Actuate Therapeutics
Prelude Therapeutics
Merck Sharp & Dohme Corp.
Elly Lilly and Company
Celgene Corporation
OncoMed Pharmaceuticals
Report Scope:
In this report, the Global Adenoid Cystic Carcinoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Adenoid Cystic Carcinoma Market, By Drug Class:
Cytotoxic Drugs
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Adenoid Cystic Carcinoma Market, By Treatment:
Surgery
Radiation Therapy
Chemotherapy
Targeted Therapy
Adenoid Cystic Carcinoma Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Adenoid Cystic Carcinoma Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Adenoid Cystic Carcinoma Market.
Available Customizations:
Global Adenoid Cystic Carcinoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Adenoid Cystic Carcinoma Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (Cytotoxic Drugs, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others)
4.2.2. By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy)
4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Treatment
4.3.3. By Distribution Channel
4.3.4. By Region
5. Asia Pacific Adenoid Cystic Carcinoma Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Treatment
5.2.3. By Distribution Channel
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Adenoid Cystic Carcinoma Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Treatment
5.3.1.2.3. By Distribution Channel
5.3.2. India Adenoid Cystic Carcinoma Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Treatment
5.3.2.2.3. By Distribution Channel
5.3.3. Australia Adenoid Cystic Carcinoma Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Treatment
5.3.3.2.3. By Distribution Channel
5.3.4. Japan Adenoid Cystic Carcinoma Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Treatment
5.3.4.2.3. By Distribution Channel
5.3.5. South Korea Adenoid Cystic Carcinoma Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Treatment
5.3.5.2.3. By Distribution Channel
6. Europe Adenoid Cystic Carcinoma Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Treatment
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Adenoid Cystic Carcinoma Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Treatment
6.3.1.2.3. By Distribution Channel
6.3.2. Germany Adenoid Cystic Carcinoma Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Treatment
6.3.2.2.3. By Distribution Channel
6.3.3. Spain Adenoid Cystic Carcinoma Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Treatment
6.3.3.2.3. By Distribution Channel
6.3.4. Italy Adenoid Cystic Carcinoma Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Treatment
6.3.4.2.3. By Distribution Channel
6.3.5. United Kingdom Adenoid Cystic Carcinoma Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Treatment
6.3.5.2.3. By Distribution Channel
7. North America Adenoid Cystic Carcinoma Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Treatment
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Adenoid Cystic Carcinoma Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Treatment
7.3.1.2.3. By Distribution Channel
7.3.2. Mexico Adenoid Cystic Carcinoma Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Treatment
7.3.2.2.3. By Distribution Channel
7.3.3. Canada Adenoid Cystic Carcinoma Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Treatment
7.3.3.2.3. By Distribution Channel
8. South America Adenoid Cystic Carcinoma Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Treatment
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Adenoid Cystic Carcinoma Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Treatment
8.3.1.2.3. By Distribution Channel
8.3.2. Argentina Adenoid Cystic Carcinoma Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Treatment
8.3.2.2.3. By Distribution Channel
8.3.3. Colombia Adenoid Cystic Carcinoma Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Treatment
8.3.3.2.3. By Distribution Channel
9. Middle East and Africa Adenoid Cystic Carcinoma Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Treatment
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Adenoid Cystic Carcinoma Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Treatment
9.3.1.2.3. By Distribution Channel
9.3.2. Saudi Arabia Adenoid Cystic Carcinoma Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Treatment
9.3.2.2.3. By Distribution Channel
9.3.3. UAE Adenoid Cystic Carcinoma Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Treatment
9.3.3.2.3. By Distribution Channel
9.3.4. Egypt Adenoid Cystic Carcinoma Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Treatment
9.3.4.2.3. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Adenoid Cystic Carcinoma Market: SWOT Analysis
